THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED DATED 28 SEPTEMBER 2007...Evotec SE • October 8th, 2021 • Pharmaceutical preparations
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND DISCLOSED REDMOND RIDGE CORPORATE CENTER LEASE BY AND BElWEEN M&T PARTNERS, INC., a Delaware corporation...Evotec SE • October 8th, 2021 • Pharmaceutical preparations
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED INVESTMENT AGREEMENT AMONG...Investment Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH THE COMPANY IF PUBLICLY DISCLOSED Drug Discovery & Development Services Agreement Evotec International GmbH and Novo Nordisk A/SDevelopment Services Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
NOW, THEREFORE, the Parties hereby acknowledge, and intend to be legally bound, and otherwise be bound by proper and reasonable conduct, agree as follows:
Promissory Notes (Schuldscheindarlehen)Promissory Notes • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
The seven promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender.
Drug Discovery & Development Services Agreement Aptuit (Verona) Srl and Novo Nordisk A/SDevelopment Services Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
NOW, THEREFORE, the Parties hereby acknowledge, and intend to be legally bound, and otherwise be bound by proper and reasonable conduct, agree as follows:
C L I F F O R D C H A N C E CLIFFORD CHANCE LLPEvotec SE • October 8th, 2021 • Pharmaceutical preparations • Luxembourg
In this Agreement any reference to a “Clause” is, unless the context otherwise requires, a reference to a Clause in this Agreement.
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESEARCH COLLABORATION AND...Research Collaboration and License Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations • England and Wales
WHEREAS, Novo is a global research-based pharmaceutical company which, inter alia, is engaged in the research, development and commercialization of pharmaceutical products;
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SHARE PURCHASE AGREEMENT...Share Purchase Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
Whereas, Seller owns 99,506,831 shares (the “Transferred Shares”), representing 100% of the share capital of the Biopark By Sanofi, a French société par actions simplifiée, with a share capital of 9,950,683.10 euros, whose registered office is located at 195, route d’Espagne, 31036 Toulouse Cedex (France), registered with the Trade and Commercial Registry of Toulouse under number 808 635 056 (the “Company”).
Lease Agreement – Essener Bogen 7Lease Agreement • October 8th, 2021 • Evotec SE • Pharmaceutical preparations
Since January 1 2011, Evotec AG (the “Company”) has rented office and laboratory space located at Essener Bogen 7 in Hamburg, Germany. The current monthly gross rent amounts to EUR 164,266.34, including ancillary costs of EUR 7,000. The landlord for the property is EuroCore Magnet S.à r.l (the “Landlord”). To date, the lease has been amended eight times.
